Key points are not available for this paper at this time.
Once-daily relugolix combination therapy resulted in a significant reduction in menstrual bleeding, as compared with placebo, and preserved bone mineral density in women with uterine fibroids. (Funded by Myovant Sciences; LIBERTY 1 L1 and LIBERTY 2 L2 ClinicalTrials.gov numbers, NCT03049735 and NCT03103087, respectively.).
Al‐Hendy et al. (Wed,) studied this question.